03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
18:17 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Regeneron and Sanofi report Phase I response data for cemiplimab in NSCLC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) reported interim data from 21 evaluable patients with advanced non-small cell lung cancer (NSCLC) from the dose-escalation portion or an expansion cohort of a Phase I trial...
16:07 , May 4, 2018 |  BC Week In Review  |  Clinical News

Sanofi, Regeneron anti-PD-1 mAb gets Priority Review

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted and granted Priority Review to a BLA for cemiplimab (REGN2810; SAR439684) to treat metastatic cutaneous squamous cell carcinoma (CSCC) or advanced CSCC in...
16:09 , Apr 30, 2018 |  BC Extra  |  Company News

Sanofi, Regeneron anti-PD-1 mAb gets Priority Review

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted and granted Priority Review to a BLA for cemiplimab (REGN2810; SAR439684) to treat metastatic cutaneous squamous cell carcinoma (CSCC) or advanced CSCC in...
17:48 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

EMA accepts MAA for Sanofi's cemiplimab

Sanofi (Euronext:SAN; NYSE:SNY) said EMA accepted for review an MAA for cemiplimab to treat metastatic cutaneous squamous cell carcinoma. The MAA is based on data from the single-arm, open-label Phase II EMPOWER-CSCC 1 trial, in...
20:56 , Apr 3, 2018 |  BC Extra  |  Company News

EMA accepts MAA for Sanofi’s anti-PD-1 mAb

Sanofi (Euronext:SAN; NYSE:SNY) said EMA accepted for review an MAA for cemiplimab to treat metastatic cutaneous squamous cell carcinoma. The pharma is developing the therapy in partnership with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Cemiplimab is a human...
23:14 , Feb 14, 2018 |  BC Extra  |  Preclinical News

TGFB inhibition could treat checkpoint inhibitor-resistant cancer

In two studies published in Nature, scientists uncovered the role of transforming growth factor (TGF) beta in the tumor microenvironment, and suggested that blocking TGF beta could help treat cancers resistant to checkpoint inhibitor therapies. In...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
21:04 , Jan 12, 2018 |  BC Week In Review  |  Company News

Sanofi, Regeneron expand 2015 immuno-oncology agreement

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded a 2015 immuno-oncology deal to increase and accelerate investment in the clinical development of anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) for cancer and Dupixent dupilumab (REGN668, SAR231893)...